Current Allergy and Asthma Reports

, Volume 9, Issue 4, pp 286–290 | Cite as

Basophil responsiveness in chronic urticaria

Article

Abstract

Chronic urticaria is a common skin disease without an etiology in the majority of cases. The similarity of symptoms and pathology to allergen-induced skin reactions supports the idea that skin mast cell and blood basophil IgE receptor activation is involved; however, no exogenous allergen trigger has been identified. Recent evidence supports a role for blood basophils in disease expression. Specifically, blood basopenia is noted in active disease with the recruitment of blood basophils to skin lesional sites. In addition, blood basophils display altered IgE receptor-mediated degranulation that reverts in disease remission. In active chronic idiopathic urticaria (CIU) subjects, changes in IgE receptor-signaling molecule expression levels accompany the altered degranulation function in blood basophils. The arrival of therapies targeting IgE has further shown that altered blood basophil degranulation behavior has potential use as a disease biomarker in CIU.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Greaves M: Chronic urticaria. J Allergy Clin Immunol 2000, 105:664–672.PubMedCrossRefGoogle Scholar
  2. 2.
    Kaplan AP: Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004, 114:465–474.PubMedCrossRefGoogle Scholar
  3. 3.
    Toubi E, Kessel A, Avshovich N, et al.: Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004, 59:869–873.PubMedCrossRefGoogle Scholar
  4. 4.
    Grob JJ, Revuz J, Ortonne JP, et al.: Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005, 152:289–295.PubMedCrossRefGoogle Scholar
  5. 5.
    O’Donnell BF, Lawlor F, Simpson J, et al.: The impact of chronic urticaria on the quality of life. Br J Dermatol 1997, 136:197–201.PubMedCrossRefGoogle Scholar
  6. 6.
    Delong LK, Culler SD, Saini SS, et al.: Annual direct and indirect costs of chronic idiopathic urticaria: a cost analysis of fifty non-immunocompromised patients. Arch Dermatol 2008, 144:35–39.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith CH, Kepley C, Schwartz LB, Lee TH: Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol 1995, 96:360–364.PubMedCrossRefGoogle Scholar
  8. 8.
    Jacques P, Lavoie A, Bedard PM, et al.: Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission. J Allergy Clin Immunol 1992, 89:1139–1143.PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen RW, Rosenstreich DL: Discrimination between urticaria-prone and other allergic patients by intradermal skin testing with codeine. J Allergy Clin Immunol 1986, 77:802–807.PubMedCrossRefGoogle Scholar
  10. 10.
    Ying S, Kikuchi Y, Meng Q, et al.: TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002, 109:694–700.PubMedCrossRefGoogle Scholar
  11. 11.
    Sabroe RA, Poon E, Orchard GE, et al.: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999, 103:484–493.PubMedCrossRefGoogle Scholar
  12. 12.
    Caproni M, Volpi W, Macchia D, et al.: Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test. Exp Dermatol 2003, 12:621–628.PubMedCrossRefGoogle Scholar
  13. 13.
    Gruber BL, Baeza ML, Marchese MJ, et al.: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988, 90:213–217.PubMedCrossRefGoogle Scholar
  14. 14.
    Hide M, Francis DM, Grattan CE, et al.: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993, 328:1599–1604.PubMedCrossRefGoogle Scholar
  15. 15.
    Brodell LA, Beck LA, Saini SS: Pathophysiology of chronic urticaria. Ann Allergy Asthma Immunol 2008, 100:291–297.PubMedCrossRefGoogle Scholar
  16. 16.
    Sheikh J: Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol 2005, 5:403–407.PubMedCrossRefGoogle Scholar
  17. 17.
    Karasuyama H, Mukai K, Tsujimura Y, Obata K: Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol 2009, 9:9–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Mukai K, Obata K, Tsujimura Y, Karasuyama H: New insights into the roles for basophils in acute and chronic allergy. Allergol Int 2009, 58:11–19.PubMedCrossRefGoogle Scholar
  19. 19.
    Obata K, Mukai K, Tsujimura Y, et al.: Basophils are essential initiators of a novel type of chronic allergic inflammation. Blood 2007, 110:913–920.PubMedCrossRefGoogle Scholar
  20. 20.
    Grattan CE, Dawn G, Gibbs S, Francis DM: Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003, 33:337–341.PubMedCrossRefGoogle Scholar
  21. 21.
    Caproni M, Giomi B, Volpi W, et al.: Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005, 114:284–292.PubMedCrossRefGoogle Scholar
  22. 22.
    Schleimer RP, Lichtenstein LM, Gillespie E: Inhibition of basophil histamine release by anti-inflammatory steroids. Nature 1981, 292:454–455.PubMedCrossRefGoogle Scholar
  23. 23.
    Charlesworth EN, Kagey-Sobotka A, Schleimer RP, et al.: Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol 1991, 146:671–676.PubMedGoogle Scholar
  24. 24.
    Grattan CE, Walpole D, Francis DM, et al.: Flow cytometric analysis of basophil numbers in chronic urticaria: basopenia is related to serum histamine releasing activity. Clin Exp Allergy 1997, 27:1417–1424.PubMedCrossRefGoogle Scholar
  25. 25.
    Greaves MW, Plummer VM, McLaughlan P, Stanworth DR: Serum and cell bound IgE in chronic urticaria. Clin Allergy 1974, 4:265–271.PubMedCrossRefGoogle Scholar
  26. 26.
    Kern F, Lichtenstein LM: Defective histamine release in chronic urticaria. J Clin Invest 1976, 57:1369–1377.PubMedCrossRefGoogle Scholar
  27. 27.
    Sabroe RA, Francis DM, Barr RM, et al.: Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 1998, 102:651–658.PubMedCrossRefGoogle Scholar
  28. 28.
    Luquin E, Kaplan AP, Ferrer M: Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli. Clin Exp Allergy 2005, 35:456–460.PubMedCrossRefGoogle Scholar
  29. 29.
    Vonakis BM, Vasagar K, Gibbons J, et al.: Basophil FceRI histamine release parallels expression of Src-homology2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 2007, 119:441–448.PubMedCrossRefGoogle Scholar
  30. 30.
    Vasagar K, Vonakis BM, Gober L, et al.: Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 2006, 36:770–776.PubMedCrossRefGoogle Scholar
  31. 31.
    Lourenco FD, Azor MH, Santos JC, et al.: Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. Br J Dermatol 2008, 158:979–986.PubMedCrossRefGoogle Scholar
  32. 32.
    Kepley CL, Youssef L, Andrews RP, et al.: Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol 1999, 104:279–284.PubMedCrossRefGoogle Scholar
  33. 33.
    Macglashan D, Miura K: Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol 2004, 114:1317–1324.PubMedCrossRefGoogle Scholar
  34. 34.
    Macglashan DW Jr: Relationship between spleen tyrosine kinase and phosphatidylinositol 5′ phosphatase expression and secretion from human basophils in the general population. J Allergy Clin Immunol 2007, 119:626–633.PubMedCrossRefGoogle Scholar
  35. 35.
    Harris SJ, Parry RV, Westwick J, Ward SG: Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. J Biol Chem 2008, 283:2465–2469.PubMedCrossRefGoogle Scholar
  36. 36.
    Kimura T, Sakamoto H, Appella E, Siraganian RP: The negative signaling molecule SH2 domain-containing inositol-polyphosphate 5-phosphatase (SHIP) binds to the tyrosine-phosphorylated beta subunit of the high affinity IgE receptor. J Biol Chem 1997, 272:13991–13996.PubMedCrossRefGoogle Scholar
  37. 37.
    Gimborn K, Lessmann E, Kuppig S, et al.: SHIP down-regulates FcepsilonR1-induced degranulation at supraoptimal IgE or antigen levels. J Immunol 2005, 174:507–516.PubMedGoogle Scholar
  38. 38.
    Huber M, Helgason CD, Damen JE, et al.: The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci U S A 1998, 95:11330–11335.PubMedCrossRefGoogle Scholar
  39. 39.
    Vonakis BM, Gibbons S Jr, Sora R, et al.: Src homology 2 domain-containing inositol 5′ phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils. J Allergy Clin Immunol 2001, 108:822–831.PubMedCrossRefGoogle Scholar
  40. 40.
    Gibbs BF, Rathling A, Zillikens D, et al.: Initial Fc epsilon RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation. J Allergy Clin Immunol 2006, 118:1060–1067.PubMedCrossRefGoogle Scholar
  41. 41.
    Leung WH, Bolland S: The inositol 5′-phosphatase SHIP-2 negatively regulates IgE-induced mast cell degranulation and cytokine production. J Immunol 2007, 179:95–102.PubMedGoogle Scholar
  42. 42.
    Vonakis BM, Saini SS: Syk-deficientbasophils from donors with chronic idiopathic urticaria exhibit a spectrum of releasability. J Allergy Clin Immunol 2008, 121:262–264.PubMedCrossRefGoogle Scholar
  43. 43.
    Eckman J, Hamilton RG, Gober LM, et al.: Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008, 128:1956–1963.PubMedGoogle Scholar
  44. 44.
    Baker R, Vasagar K, Ohameje N, et al.: Basophil histamine release activity and disease severity in chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2008, 100:244–249.PubMedGoogle Scholar
  45. 45.
    Morgan M, Khan DA: Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1. Ann Allergy Asthma Immunol 2008, 100:403–412.PubMedGoogle Scholar
  46. 46.
    Gober L, Sterba P, Eckman J, Saini S: Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria patients. J Allergy Clin Immunol 2008, 121:S147.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Johns Hopkins Asthma and Allergy CenterBaltimoreUSA

Personalised recommendations